ArticleBMC infectious diseases2016
A novel multi-epitope recombined protein for diagnosis of human brucellosis.
Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- IgM and IgG Epitope Mapping of the Porin Outer Membrane Protein-2a fromInternational journal of molecular sciences · 2026Article
- Multiepitope fusion protein-based ELISA for enhanced brucellosis serodiagnosis.PLoS neglected tropical diseases · 2025Article
- AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus.Journal of chemical information and modeling · 2025Article
- Article
- Article
- A multi-epitope vaccine targeting a key virulence factor ClfA: An In-silico approach to combat Staphylococcus aureus infections.PloS one · 2025Article
- Immuno-informatics voyage through molecular mimicry of Heat Shock Proteins: Potential IBD immunopathogenesis.PloS one · 2025Article
- Recombinant multiepitope proteins expressed in Escherichia coli cells and their potential for immunodiagnosis.Microbial cell factories · 2024Review
- In Silico Design of a New Epitope-Based Vaccine against Grass Group 1 Allergens.Advances in respiratory medicine · 2023Article
- Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs.Frontiers in immunology · 2023Article
- A subunit vaccine against pneumonia: targeting SNetwork modeling and analysis in health informatics and bioinformatics · 2023Article
- Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants.Computational biology and chemistry · 2022Article
- A Promising Tool in Serological Diagnosis: Current Research Progress of Antigenic Epitopes in Infectious Diseases.Pathogens (Basel, Switzerland) · 2022Review
- In silico designing of a recombinant multi-epitope antigen for leprosy diagnosis.Journal, genetic engineering & biotechnology · 2022Article
- Development of a diagnostic indirect ELISA test for detection ofVeterinary research forum : an international quarterly journal · 2022Article
- Design of a multi-epitope vaccine against SARS-CoV-2: immunoinformatic and computational methods.RSC advances · 2022Article
- A multiepitope vaccine candidate against infectious bursal disease virus using immunoinformatics-based reverse vaccinology approach.Frontiers in veterinary science · 2022Article
- Rapid detection ofRSC advances · 2021Article
- Article
- Evaluation of chimeric proteins for serological diagnosis of brucellosis in cattle.Veterinary world · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn epidemic regions of the world, brucellosis is a reemerging zoonosis with minimal mortality but is a serious public hygiene problem. Currently, there are various methods for brucellosis diagnosis, however few of them are available to be used to diagnose, especially for serious cross-reaction with other bacteria.
methodTo overcome this disadvantage, we explored a novel multi-epitope recombinant protein as human brucellosis diagnostic antigen. We established an indirect enzyme-linked immunosorbent assay (ELISA) based on this recombinant protein. 248 sera obtained from three different groups including patients with brucellosis (146 samples), non-brucellosis patients (82 samples), and healthy individuals (20 samples) were tested by indirect ELISA. To evaluate the assay, a receiver-operating characteristic (ROC) analysis and immunoblotting were carried out using these characterized serum samples.
resultsFor this test, the area under the ROC curve was 0.9409 (95 % confidence interval, 0.9108 to 0.9709), and a sensitivity of 88.89 % and a specificity of 85.54 % was given with a cutoff value of 0.3865 from this ROC analysis. The Western blot results indicate that it is feasible to differentiate human brucellosis and non-brucellosis with the newly established method based on this recombinant protein.
conclusionOur results obtained high diagnostic accuracy of the ELISA assay which encourage the use of this novel recombinant protein as diagnostic antigen to implement serological diagnosis of brucellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.